Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to induce and maintain remission as quickly as possible. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. However, the pediatric CD treatment algorithm continues to evolve, and physicians increasingly initiate treatment with TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira), especially in patients with more-severe disease symptoms. The non-TNF biologics, including Takeda’s Entyvio and Janssen’s Stelara, may also be prescribed, particularly after anti-TNF failure.
Longitudinal patient-level claims data analysis
Key Drugs Covered
Humira, Remicade / biosimilar infliximab, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants
Key Analysis Provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.